Insider Buying: Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Acquires 1,920 Shares of Stock

Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Nick Pizzie bought 1,920 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average cost of $20.80 per share, for a total transaction of $39,936.00. Following the completion of the purchase, the chief financial officer now owns 1,920 shares in the company, valued at $39,936. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nick Pizzie also recently made the following trade(s):

  • On Tuesday, March 19th, Nick Pizzie bought 5,400 shares of Axsome Therapeutics stock. The shares were acquired at an average cost of $12.58 per share, for a total transaction of $67,932.00.

Shares of NASDAQ:AXSM traded up $0.90 during trading hours on Thursday, reaching $23.02. The stock had a trading volume of 599,354 shares, compared to its average volume of 1,270,137. Axsome Therapeutics Inc has a 1 year low of $1.94 and a 1 year high of $26.45. The company has a current ratio of 5.68, a quick ratio of 5.68 and a debt-to-equity ratio of 1.08. The company has a market cap of $736.82 million, a PE ratio of -20.02 and a beta of 2.78.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.01). As a group, equities research analysts expect that Axsome Therapeutics Inc will post -1.29 EPS for the current year.

Several large investors have recently made changes to their positions in AXSM. Barclays PLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $30,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Axsome Therapeutics by 113.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,400 shares of the company’s stock valued at $48,000 after purchasing an additional 1,809 shares during the last quarter. Focused Wealth Management Inc purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $64,000. Bank of New York Mellon Corp purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $98,000. Finally, Weiss Asset Management LP purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $171,000. 44.22% of the stock is currently owned by institutional investors.

Several equities research analysts recently weighed in on AXSM shares. BidaskClub downgraded shares of Axsome Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, March 3rd. HC Wainwright set a $15.00 target price on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald upped their target price on shares of Axsome Therapeutics from $13.00 to $16.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. Finally, BTIG Research upped their target price on shares of Axsome Therapeutics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $30.83.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://theenterpriseleader.com/2019/06/13/insider-buying-axsome-therapeutics-inc-nasdaqaxsm-cfo-acquires-1920-shares-of-stock.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.